Drug Type Biosimilar, Monoclonal antibody |
Synonyms Nivolumab Biosimilar (Wincal Biopharm Inc.), 纳武利尤单抗生物类似药(Wincal Biopharm Inc.) |
Target |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uveal Melanoma | Preclinical | US | 22 May 2023 |